AKTX
Akari Therapeutics, Plc
1W: -43.2%
1M: -44.9%
3M: -48.1%
YTD: -55.1%
1Y: -89.6%
3Y: -97.5%
5Y: -99.8%
$0.13
-0.02 (-10.65%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.13-1.58
Volume341,962
Avg Volume442,162
Beta0.34
Dividend—
Analyst Ratings
Company Info
CEOAbizer Gaslightwala
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2014-01-06
Websiteakaritx.com
75/76 Wimpole Street
London W1G 9RT
GB
London W1G 9RT
GB
44 20 8004 0270
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Latest News
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Neal James R | P-Purchase | 2,473 | $0.39 | 2025-12-16 |
| Neal James R | P-Purchase | 2,473 | — | 2025-12-16 |
| Neal James R | P-Purchase | 3,093 | $0.39 | 2025-12-16 |
| Neal James R | P-Purchase | 3,093 | — | 2025-12-16 |
| Prudo-Chlebosz Raymo | P-Purchase | 618,658 | $0.39 | 2025-12-16 |